Drug Guidance for Subsidy 16/09/2025 Fruquintinib for previously treated metastatic colorectal cancer The Ministry of Health’s Drug Advisory Committee has recommended: Fruquintinib 1 mg and 5 mg ... See all × 16/09/2025 Fruquintinib for previously treated metastatic colorectal cancer The Ministry of Health’s Drug Advisory Committee has recommended: Fruquintinib 1 mg and 5 mg capsules for treating patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, anti-VEGF therapy, and if RAS wild-type, anti-EGFR therapy. Funding status RFruquintinib 1 mg and 5 mg capsules are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 November 2025. Clinical indication, subsidy class and MediShield Life claim limit for fruquintinib are provided in the Annex.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Capsule 1 mg National Cancer Centre Capsule 5 mg National Cancer Centre
ORAL Select a brand starting with the letter: F FRUZAQLA CAPSULE 1MG [SIN17114P] FRUZAQLA CAPSULE 5MG [SIN17113P]